ClC1[N:3]=[C:4]([N:13]2[CH2:18][CH2:17]OCC2)[C:5]2SC(C=O)=C[C:6]=2N=1.C(N1CCN[C@@H](C)C1)(C1C=CC=CC=1)(C1C=CC=CC=1)C1C=CC=CC=1.Cl.[OH-].[Na+].C[C@H]1CNCCN1CC1N=C(N2CCOCC2)C2SC=CC=2N=1.C(O)(=O)C(C)O.Cl[C:78]1[N:79]=[C:80]([N:100]2[CH2:105][CH2:104][O:103][CH2:102][CH2:101]2)[C:81]2[S:86][C:85]([CH2:87][N:88]3[CH2:93][CH2:92][N:91]([C:94](=[O:98])[C@@H:95]([OH:97])[CH3:96])[CH2:90][C@@H:89]3[CH3:99])=[CH:84][C:82]=2[N:83]=1.CC1(C)C(C)(C)OB(C2C=CC(N)=NC=2)O1>CO>[NH2:3][C:4]1[N:13]=[CH:18][C:17]([C:78]2[N:79]=[C:80]([N:100]3[CH2:105][CH2:104][O:103][CH2:102][CH2:101]3)[C:81]3[S:86][C:85]([CH2:87][N:88]4[CH2:93][CH2:92][N:91]([C:94](=[O:98])[C@@H:95]([OH:97])[CH3:96])[CH2:90][C@@H:89]4[CH3:99])=[CH:84][C:82]=3[N:83]=2)=[CH:6][CH:5]=12-Chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde 10 from Example 3 (200 mg) was used according to General Procedure B-3 with (S)-4-N-trityl-2-methyl-piperazine. The crude product was then dissolved in 10 mL of methanol and reacted with 0.5 mL of concentrated HCl for several hours before basifying with NaOH and extracting into EtOAc. After evaporation the crude reaction mixture containing 200 mg of 2-chloro-6-(((S)-2-methylpiperazin-1-yl)methyl-4-morpholinothieno[3,2-d]pyrimidine was reacted with lactic acid via General Procedure B-2. 120 mg of (S)-1-((S)-4-((2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)-3-methylpiperazin-1-yl)-2-hydroxypropan-1-one was reacted with 88 mg of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine via General Procedure A to give 19.6 mg of 193. MS (Q1) 498.3 (M)+.
読み込み中…